Menu Search
Equities

Episurf Medical AB

16E:BER

Episurf Medical AB

Actions
  • Price (EUR)0.0193
  • Today's Change0.001 / 5.46%
  • Shares traded15.00k
  • 1 Year change-76.79%
  • Beta--
Data delayed at least 15 minutes, as of Nov 13 2024 16:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Episurf Medical AB is a Sweden-based medical technology company. It is engaged in the development, manufacture and marketing of implants and surgical drilling templates used in the treatment of local cartilage damage in knee joints. The Company’s product portfolio includes the Episealer, and individually customized implant used as a cartilage replacement for early-stage patients; and Epiguide, a drill guide designed to attach to the knee’s surface, as well as related surgical tools. The personalization of implants and instruments is based on magnetic resonance imaging (MRI) and enables less invasive treatment. The process of ordering and creation of patient-specific implants and surgical instruments is covered by software suite, microiFidelity, comprising microiClinic, microiDesign and microiManufacture. The main shareholder of the Company is Serendipity Ixora Fund AB.

  • Revenue in SEK (TTM)12.80m
  • Net income in SEK-79.70m
  • Incorporated2008
  • Employees26.00
  • Location
    Episurf Medical ABKarlavagen 60STOCKHOLM 114 49SwedenSWE
  • Phone+46 86120020
  • Websitehttps://episurf.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.